1.
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
by Fayad, Zahi A, Prof
The Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559

2.
Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)
by Woodward, Mark
Heart (British Cardiac Society), 2007-02, Vol.93 (2), p.172-176

3.
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
by Muntner, Paul, PhD
The American heart journal, 2011, Vol.161 (4), p.719-725

4.
Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fl...
by Fayad, Zahi A., PhD
The American heart journal, 2011, Vol.162 (2), p.214-221.e2

5.
Effects of Prehypertension and Hypertension Subtype on Cardiovascular Disease in the Asia-Pacific Region
by Arima, Hisatomi
Hypertension (Dallas, Tex. 1979), 2012-06, Vol.59 (6), p.1118-1123

6.
Blood Pressure Variables and Cardiovascular Risk: New Findings From ADVANCE
by Kengne, Andre-Pascal
Hypertension (Dallas, Tex. 1979), 2009-08, Vol.54 (2), p.399-404

7.
Impact of Blood Pressure Lowering on Cardiovascular Outcomes in Normal Weight, Overweight, and Obese Individuals: The Perindopril Protection Against Recurrent Stroke Study Trial
by Czernichow, Sébastien
Hypertension (Dallas, Tex. 1979), 2010-05, Vol.55 (5), p.1193-1198
